<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Idiopathic pulmonary hemosiderosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Idiopathic pulmonary hemosiderosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Idiopathic pulmonary hemosiderosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nils Milman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Talmadge E King, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 07, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Idiopathic pulmonary hemosiderosis (IPH) is a rare disease, found primarily in children, that is characterized by recurrent episodes of diffuse alveolar hemorrhage (DAH). When no underlying cause for repeated episodes of DAH is apparent  (
         <a class="graphic graphic_table graphicRef52374" href="/z/d/graphic/52374.html" rel="external">
          table 1
         </a>
         ), the entity is referred to as IPH [
         <a href="#rid1">
          1
         </a>
         ]. Among patients with IPH, recurrent alveolar bleeding can eventually produce pulmonary hemosiderosis and fibrosis.
        </p>
        <p>
         The clinical features, treatment, and prognosis of IPH will be reviewed here. A general discussion of the DAH syndromes is provided separately. (See
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6374.html" rel="external">
          "Approach to the infant and child with diffuse lung disease (interstitial lung disease)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary defect and clinical feature in IPH is recurrent alveolar hemorrhage. The exact etiology of IPH is unknown. The favorable response to immunosuppressive therapy suggests that immune processes may be involved. A structural defect in the alveolar capillaries, either in the alveolar basement membrane or in the alveolar endothelial cell, may predispose to the condition [
         <a href="#rid1">
          1-5
         </a>
         ]. The accumulation of neutrophils in the alveoli also may play a role [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunologic abnormalities
         </strong>
         – An immunologic mechanism for recurrent alveolar hemorrhage has been suggested but not established. Immune complexes have been demonstrated in the plasma of several patients; however, immunohistochemical examination of lung tissue has not identified immune complex deposition [
         <a href="#rid2">
          2,3,7-10
         </a>
         ]. The possibility that autoimmune mechanisms play a role in IPH is suggested by the observation that approximately 25 percent of patients present with various autoantibodies at diagnosis [
         <a href="#rid11">
          11
         </a>
         ] and approximately 25 percent of patients with the condition who survive for more than 10 years subsequently develop autoimmune disorders [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Links between IPH and ingested protein antigens have also been hypothesized, based upon the following observations:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Coexistence of celiac disease and IPH, also known as Lane-Hamilton syndrome, has been reported in a large number of cases, and introduction of a gluten-free diet has been associated with remission of pulmonary symptoms in several patients with IPH [
         <a href="#rid14">
          14-22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4771.html" rel="external">
          "Diagnosis of celiac disease in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4777.html" rel="external">
          "Management of celiac disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Circulating antibodies against cow's milk have been detected in a number of children with the disorder, suggesting that IPH may be associated with a hypersensitivity reaction to milk [
         <a href="#rid23">
          23-25
         </a>
         ]. However, other investigators have failed to reproduce these findings [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Iron metabolism
         </strong>
         – The pathologic consequences of recurrent alveolar hemorrhage are likely related to accumulation of free iron in pulmonary cells and tissue, which induces formation of highly toxic free hydroxyl radicals (Fenton reaction) that can eventually lead to cell necrosis and tissue remodeling with pulmonary fibrosis [
         <a href="#rid26">
          26,27
         </a>
         ]. The mechanisms involved may be similar to those responsible for the fibrosis in the liver, pancreas, and heart that occurs in genetic (hereditary) hemochromatosis and other iron overload syndromes. (See
         <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">
          "Approach to the patient with suspected iron overload"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemochromatosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The monocyte-macrophage system, which is involved in processing free iron, displays great heterogeneity between different organs. Alveolar macrophages are less able to degrade erythrocytes and reprocess hemoglobin iron than macrophages in the liver, spleen, and bone marrow [
         <a href="#rid26">
          26,28
         </a>
         ]. It is thought that excess free iron leads to production of hydroxyl radicals and consequent tissue injury [
         <a href="#rid26">
          26,29
         </a>
         ]. However, iron induces intense production of intracellular ferritin, which normally protects the lung macrophages against free iron and oxidation [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Iron deficiency anemia is observed in IPH due to alveolar hemorrhage and depletion of body iron reserves in the liver, spleen, and bone marrow. Accumulation of substantial amounts of iron within alveolar macrophages stimulates intracellular ferritin production and iron is initially stored in ferritin molecules, which are then processed into intracellular hemosiderin complexes. The iron in hemosiderin within the alveolar macrophages becomes functionally trapped and unavailable for the synthesis of hemoglobin by erythroblasts in the bone marrow [
         <a href="#rid26">
          26
         </a>
         ]. Nevertheless, the iron trapped in intracellular hemosiderin complexes stimulates the macrophages to produce ferritin, which subsequently induces an increase in the serum ferritin level [
         <a href="#rid8">
          8
         </a>
         ]. This explains why patients can present with iron deficiency anemia despite relatively normal serum ferritin levels.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          EPIDEMIOLOGY AND RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The exact incidence and prevalence of IPH are largely unknown. A retrospective review of records from a tertiary pediatric hospital in northern Taiwan noted five cases over 25 years [
         <a href="#rid31">
          31
         </a>
         ]. A separate pediatric registry report (2008 to 2013) noted 20 girls and five boys [
         <a href="#rid32">
          32
         </a>
         ], while a literature review of adult-onset cases described almost twice as many males as females [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         Eighty percent of cases of IPH occur in children, generally manifesting before 10 years of age [
         <a href="#rid34">
          34
         </a>
         ]. In adults, most cases are recognized between 20 and 40 years of age, although IPH can occur at any age [
         <a href="#rid34">
          34
         </a>
         ]. Familial clustering has been described in several reports [
         <a href="#rid23">
          23,35,36
         </a>
         ], suggesting that hereditary factors play a role in the development of IPH and/or that environmental factors might precipitate the disease in genetically predisposed individuals [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         Older series of IPH probably included many patients who would not currently be considered to fit diagnostic criteria of the syndrome, including patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (such as granulomatosis with polyangiitis and microscopic polyarteritis nodosa) and other rheumatic disorders [
         <a href="#rid1">
          1
         </a>
         ]. Sensitive assays for detection of autoimmune antibodies, new scintigraphic methods, and less invasive techniques for lung biopsy have permitted a more refined classification of patients with diffuse alveolar hemorrhage (DAH) that were not available when early series were performed. (See
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes"
         </a>
         .)
        </p>
        <p>
         The contribution of environmental exposures as risk factors for development IPH remains speculative. Exposures to second-hand smoke and indoor molds, particularly
         <em>
          Stachybotrys chartarum
         </em>
         , have been suggested as causative factors in infants with IPH [
         <a href="#rid38">
          38-41
         </a>
         ]. Neither of these associations has been confirmed.
        </p>
        <p>
         Down syndrome may be a predisposing factor among children with IPH [
         <a href="#rid42">
          42-44
         </a>
         ]. In a registry series that included nine children with pulmonary hemosiderosis and Down syndrome, one had serologic evidence of celiac disease, one had antibodies to cow’s milk proteins, and three probably had IPH without detectable antibodies, although lung biopsy was not obtained [
         <a href="#rid42">
          42
         </a>
         ]. Children with Down syndrome tended to have more severe disease at presentation, were more likely to develop pulmonary hypertension, and were more likely to succumb to the disease, although comorbidities (eg, cardiomyopathy, sleep apnea) may have contributed to the poor prognosis.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical presentation of IPH varies from an acute onset illness with hemoptysis and dyspnea to an insidious process characterized by fatigue, anemia, and slowly progressive exertional dyspnea. In some cases, anemia is the presenting manifestation.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Symptoms and signs
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Children
         </strong>
         – IPH often begins in children with recurrent episodes of dyspnea (68 to 85 percent), cough (48 to 100 percent), and fever (73 percent) [
         <a href="#rid32">
          32,45
         </a>
         ]. Initially, the cough is predominantly nonproductive. Hemoptysis, occasionally with large amounts of expectorated blood, occurs in 44 to 58 percent, depending on the series [
         <a href="#rid32">
          32,42,45
         </a>
         ]. Younger children are less likely to expectorate. Growth failure and moderate to severe anemia may be the presenting findings [
         <a href="#rid1">
          1,46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         On examination, pallor, cough, and tachypnea (at rest or with exertion) may be prominent. Lung examination may reveal clear lungs or crackles [
         <a href="#rid1">
          1
         </a>
         ]. Approximately 20 percent of patients have enlargement of the liver and/or spleen [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adults
         </strong>
         – Most adults with IPH present before 40 years of age, but initial presentations up to age 83 have been reported [
         <a href="#rid33">
          33
         </a>
         ]. The most frequent presenting symptoms in adults are hemoptysis (81 percent), exertional dyspnea (64 percent), and fatigue possibly due to iron deficiency anemia [
         <a href="#rid8">
          8
         </a>
         ]. Hemoptysis may range from occasional blood-streaked sputum to daily significant hemoptysis [
         <a href="#rid8">
          8,23,33,35
         </a>
         ]. Rapid asphyxiation due to massive pulmonary hemorrhage has been reported [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4394.html" rel="external">
          "Evaluation and management of life-threatening hemoptysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Associated signs in adults include fever (14 percent), crackles, and clubbing of the fingers (8 percent) [
         <a href="#rid1">
          1,33
         </a>
         ]. Case reports describe crackles in some patients [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Iron deficiency anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Iron deficiency anemia, which can range from mild to severe, is generally the sole laboratory abnormality in patients with IPH, although neutropenia and eosinophilia have been reported 5 to 10 days before the onset of episodes of alveolar hemorrhage [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Bone marrow biopsy typically shows hyperplastic erythropoiesis, usually without stainable hemosiderin iron [
         <a href="#rid8">
          8,47
         </a>
         ]. Based on estimates of the mean erythrocyte survival time, the circulating survival time of erythrocytes is reduced due to extravasation in the lungs [
         <a href="#rid8">
          8
         </a>
         ]. Plasma bilirubin and urinary excretion of urobilinogen may be increased. (See
         <a class="medical medical_review" href="/z/d/html/7150.html" rel="external">
          "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">
          "Diagnostic approach to anemia in adults"
         </a>
         .)
        </p>
        <p>
         Several caveats apply to understanding anemia in patients with IPH:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Following a bleeding episode, a high number of reticulocytes may be present in the blood, mimicking hemolytic anemia. However, specific tests for hemolysis are negative [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Since hemorrhagic sputum is often swallowed, children often present with a positive test for fecal occult blood. This can result in a fruitless search for a source of gastrointestinal bleeding. (See
         <a class="medical medical_review" href="/z/d/html/2544.html" rel="external">
          "Evaluation of occult gastrointestinal bleeding"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum ferritin concentration is generally higher in IPH than one would expect in anemia due to other types of blood loss, because serum ferritin reflects the nonmobilizable hemosiderin iron located in the alveolar macrophages in the lungs of patients with IPH [
         <a href="#rid49">
          49,50
         </a>
         ]. Cases of IPH with normal or even elevated serum ferritin despite iron deficiency anemia (ie, absent bone marrow iron) have been reported [
         <a href="#rid8">
          8,46
         </a>
         ]. This can mislead the clinician, who may think that iron deficiency can be excluded with a normal or elevated serum ferritin. Therefore, histochemical estimation of bone marrow iron in a bone marrow aspirate is important in patients with IPH as well as in other patients with diffuse alveolar hemorrhage (DAH) syndromes.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2475554014">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation of suspected IPH follows steps to assess the severity of respiratory impairment and anemia, confirm alveolar hemorrhage, and narrow the broad differential diagnosis of diffuse alveolar hemorrhage (DAH)  (
         <a class="graphic graphic_table graphicRef52374" href="/z/d/graphic/52374.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1523821498">
         <span class="h2">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to the evaluation of patients with suspected IPH aims to confirm the presence of alveolar hemorrhage and exclude other causes of DAH  (
         <a class="graphic graphic_table graphicRef57788" href="/z/d/graphic/57788.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef119265" href="/z/d/graphic/119265.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         We include the following steps:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assess blood cell counts and determine whether iron deficiency anemia is present  (
         <a class="graphic graphic_table graphicRef76236" href="/z/d/graphic/76236.html" rel="external">
          table 3
         </a>
         ). Iron deficiency anemia in a patient with hemoptysis may suggest acute on chronic bleeding. (See
         <a class="medical medical_review" href="/z/d/html/7150.html" rel="external">
          "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screening tests for coagulopathy (eg, platelet count, prothrombin time, international normalized ratio, and partial thromboplastin time).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urinalysis to assess for pulmonary-renal syndrome (eg, granulomatosis with polyangiitis, microscopic polyangiitis, anti-glomerular basement membrane disease).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screen for autoimmune disorders, such as antinuclear antibodies (ANA), anti-double-stranded deoxyribonucleic acid (anti-dsDNA), antineutrophil cytoplasmic antibodies (ANCA), anti-glomerular basement membrane (GBM) antibodies, antiphospholipid (APL) antibodies, rheumatoid factor, cryoglobulins  (
         <a class="graphic graphic_table graphicRef57788" href="/z/d/graphic/57788.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes", section on 'Laboratory testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obtain additional tests to exclude infection, if the clinical presentation is similar to acute respiratory distress syndrome. (See
         <a class="medical medical_review" href="/z/d/html/1637.html" rel="external">
          "Acute respiratory distress syndrome: Clinical features, diagnosis, and complications in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the clinical suspicion for IPH is high, screen for celiac disease. (See
         <a class="local">
          'Laboratory testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obtain high resolution chest computed tomography (HRCT). Typical findings include ground glass opacities that may be diffuse or patchy. (See
         <a class="local">
          'Imaging'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perform flexible bronchoscopy with sequential bronchoalveolar lavage (BAL) in an area of apparent radiographic involvement, or if diffuse involvement, a dependent lobe (eg, the right middle lobe). Sequential BAL with progressively more hemorrhagic effluent is one way to diagnosis alveolar hemorrhage. Hemosiderin-laden alveolar macrophages are a sign of recurrent or chronic alveolar hemorrhage and are almost always present in BAL fluid in IPH. They confirm the presence of alveolar hemorrhage but cannot be used as the sole diagnostic criterion for IPH. (See
         <a class="local">
          'Bronchoscopy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obtain lung biopsy if confident diagnosis cannot be made based on laboratory testing and BAL. (See
         <a class="local">
          'Lung biopsy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2158413203">
         <span class="h2">
          Laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         No laboratory tests are specific for IPH, so testing is designed to identify other potential causes of alveolar hemorrhage  (
         <a class="graphic graphic_table graphicRef57788" href="/z/d/graphic/57788.html" rel="external">
          table 2
         </a>
         ). The selection of tests may be adjusted depending on whether the patient presents with acute alveolar hemorrhage or a history of recurrent episodes of dyspnea associated with hemoptysis, and whether prior testing is available. In general, the goals of testing are to assess for iron deficiency anemia and celiac disease, exclude bleeding disorders and alternative processes in the differential diagnosis.
        </p>
        <p>
         Screening for celiac disease with a serologic test for IgA anti-tissue transglutaminase (TTG) antibodies may yield a diagnosis of Lane Hamilton syndrome [
         <a href="#rid20">
          20,21
         </a>
         ]. Occasional (2 to 10 percent) false negatives are noted (eg, IgA deficiency, gluten-free diet), so additional testing may be necessary in some patients, such as IgG antibody against synthetic deamidated gliadin peptides (IgG anti-dGli) and HLA-DQ2/DQ8. (See
         <a class="medical medical_review" href="/z/d/html/4771.html" rel="external">
          "Diagnosis of celiac disease in adults"
         </a>
         .)
        </p>
        <p>
         Presence of coagulopathy, thrombocytopenia, hepatic dysfunction, or glomerulonephritis would suggest an alternate diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/5936.html" rel="external">
          "Approach to the child with bleeding symptoms"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">
          "Approach to the adult with a suspected bleeding disorder"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes"
         </a>
         .)
        </p>
        <p>
         The role of testing for antibodies to cow's milk (IgG and IgE) is unclear, as an etiologic role has not been proven. We do not routinely perform this testing. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following an acute episode with pulmonary bleeding, chest radiographs demonstrate patchy opacities that partially regress during the symptom-free phase  (
         <a class="graphic graphic_diagnosticimage graphicRef62374" href="/z/d/graphic/62374.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef50621" href="/z/d/graphic/50621.html" rel="external">
          image 2
         </a>
         ) [
         <a href="#rid8">
          8,47
         </a>
         ]. The rate of resolution of opacities depends on the magnitude of the alveolar bleeding; partial regression takes approximately four to eight weeks.
        </p>
        <p>
         On HRCT, these opacities have ground glass characteristics. Unilateral or bilateral poorly defined opacities with an alveolar filling pattern are most prominent in the middle and lower lung fields. The opacities vary in intensity according to the magnitude of alveolar bleeding and the period of time elapsed since the latest bleeding episode. A “crazy-paving” pattern is also described, with ground glass opacities due to current hemorrhage and interlobular septal thickening due to deposition of hemosiderin in the interstitium [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         Patients with long-standing disease may occasionally develop multiple honeycomb cysts, which are characteristically focal and localized predominantly to the posterior and lateral basal segments [
         <a href="#rid52">
          52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6988.html" rel="external">
          "High resolution computed tomography of the lungs"
         </a>
         .)
        </p>
        <p>
         In patients with dyspnea and suspicion of pulmonary emboli, a computed tomography pulmonary angiography or ventilation-perfusion scanning should be performed in order to confirm or exclude the diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'Computed tomography pulmonary angiography'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'Ventilation perfusion scan'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Pulmonary function tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary function tests (PFTs: spirometry, lung volumes, diffusing capacity for carbon monoxide [DLCO]) are obtained in stable patients over age 6 and typically show restrictive abnormalities, with reductions in total lung capacity (TLC), forced vital capacity (FVC), a normal or increased forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         )/FVC ratio [
         <a href="#rid8">
          8,53
         </a>
         ].
        </p>
        <p>
         DLCO may be chronically reduced in patients in whom parenchymal fibrosis has developed. On the other hand, DLCO may be increased during an acute bleeding episode, due to avid binding of carbon monoxide by hemoglobin in erythrocytes that have spilled into the alveoli, thereby producing an inappropriately high DLCO [
         <a href="#rid54">
          54
         </a>
         ]. When the intra-alveolar erythrocytes and the hemoglobin they contain are degraded, the DLCO declines to prehemorrhage levels. While theoretically helpful, measurement of DLCO in the setting of acute hemoptysis is often not feasible.
        </p>
        <p>
         Pulse oximetry may show hypoxemia, particularly during acute episodes and with exercise, and arterial blood gases may show eucapnia or hypocapnia.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Sputum examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prussian blue staining of a sputum sample may confirm the presence alveolar macrophages [
         <a href="#rid55">
          55
         </a>
         ]. However, not all patients raise sputum, and the test has a low sensitivity. Furthermore, BAL is usually needed to evaluate other causes of diffuse alveolar hemorrhage (DAH), such as infection.
        </p>
        <p>
         Inducing sputum for examination is not advisable due to the potential risk of exacerbating bleeding.
        </p>
        <p>
         In the past, gastric aspirates or gastric lavage were sometimes obtained in children who were unable to expectorate sputum, but BAL has largely replaced gastric aspirates and lavage in this setting. (See
         <a class="local">
          'Bronchoscopy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Bronchoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Flexible bronchoscopy with BAL is performed in most patients and directed to segments of the lung where the HRCT shows ground glass opacification, or a dependent area, if disease is diffuse. Three sequential instillations are performed at the same site; observation of progressively more hemorrhagic fluid with each successive lavage suggests alveolar hemorrhage. (See
         <a class="medical medical_review" href="/z/d/html/4303.html" rel="external">
          "Basic principles and technique of bronchoalveolar lavage"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">
          "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p>
         In IPH, differential cell counts of BAL fluid show a predominance of alveolar macrophages, typically containing hemosiderin  (
         <a class="graphic graphic_picture graphicRef52119" href="/z/d/graphic/52119.html" rel="external">
          picture 1
         </a>
         ). Lavage fluid is sent for microbiologic studies to exclude infectious etiologies and cytologic analysis to look for malignant cells, viral inclusion bodies, and hemosiderin-laden macrophages. Prussian blue staining is used to identify and quantitate hemosiderin-laden macrophages. Rarely, BAL is falsely negative [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="local">
          'Histopathology'
         </a>
         below.)
        </p>
        <p>
         Transbronchial forceps lung biopsy (TBLB) has a reasonable yield for providing supportive pathologic data, and it should be the biopsy procedure of first choice in stable adults and children [
         <a href="#rid56">
          56,57
         </a>
         ]. Usually, we obtain four to eight TBLB specimens from one lung, preferably taken in segments showing ground glass opacification. (See
         <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">
          "Role of lung biopsy in the diagnosis of interstitial lung disease", section on 'Transbronchial lung biopsy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106085.html" rel="external">
          "Flexible bronchoscopy in adults: Associated diagnostic and therapeutic procedures", section on 'Transbronchial biopsy'
         </a>
         .)
        </p>
        <p>
         If the TBLB specimens are inconclusive, larger specimens may be obtained by transbronchial cryobiopsy (TBCB), depending of the availability and experience of this procedure in the institution [
         <a href="#rid58">
          58
         </a>
         ]. However, TBCB carries a higher risk of complications than TBLB, especially bleeding [
         <a href="#rid59">
          59
         </a>
         ], and so far there are no reports of the use of TBCB in the diagnosis of IPH. (See
         <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">
          "Role of lung biopsy in the diagnosis of interstitial lung disease", section on 'Transbronchial cryobiopsy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3109675774">
         <span class="h2">
          Lung biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         If a diagnosis cannot be made clinically or on TBLB or TBCB specimens, larger biopsy samples, obtained by video-assisted thoracoscopic surgery (VATS) or thoracotomy, are needed for a confident diagnosis of IPH. (See
         <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">
          "Role of lung biopsy in the diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p>
         The main purpose of lung biopsy is to exclude other causes of DAH that would be treated differently, such as pulmonary capillaritis or lung-limited anti-GBM disease. The decision to proceed with a lung biopsy is partly guided by the age of the patient, severity of the disease, risk for severe procedure complications, and potential therapeutic benefit for the patient.
        </p>
        <p>
         Lung biopsy is often deferred in children with a typical clinical presentation with alveolar hemorrhage, iron deficiency anemia, and celiac disease.
        </p>
        <p>
         For an adult with no cause of DAH identifiable by history, serologic testing (ie, negative ANA, ANCA, anti-GBM antibody as well as other autoantibodies), or microbiologic studies, we typically pursue a tissue diagnosis. An exception might be a patient with known celiac disease or a positive test for IgA anti-tissue transglutaminase antibody who has no recurrences of alveolar hemorrhage on a gluten-free diet. (See
         <a class="local">
          'Treatment of concomitant celiac disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3958050343">
         <span class="h2">
          Histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lung histopathology in IPH at the time of acute alveolar hemorrhage typically shows nonspecific findings of blood-filled alveolar spaces, free hemosiderin, and macrophages containing hemosiderin [
         <a href="#rid1">
          1-3,8,60
         </a>
         ]. Prussian blue staining is used to identify hemosiderin in and around alveolar macrophages  (
         <a class="graphic graphic_picture graphicRef52119" href="/z/d/graphic/52119.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef60870" href="/z/d/graphic/60870.html" rel="external">
          picture 2
         </a>
         ). Alveolar septal thickening may be present, and type 2 pneumocyte hyperplasia is common  (
         <a class="graphic graphic_picture graphicRef78396" href="/z/d/graphic/78396.html" rel="external">
          picture 3
         </a>
         and
         <a class="graphic graphic_picture graphicRef79610" href="/z/d/graphic/79610.html" rel="external">
          picture 4
         </a>
         ). These findings are indistinguishable from anti-glomerular basement membrane disease.
        </p>
        <p>
         A key feature of IPH is the absence of histologic or immunohistochemical evidence of capillaritis, which differentiates it from processes such as granulomatosis with polyangiitis, microscopic polyangiitis, and systemic lupus erythematosus [
         <a href="#rid61">
          61,62
         </a>
         ]. In particular, infiltration with neutrophils and nuclear dust in the alveolar septa are not seen, and immune complexes are not present on immunofluorescent staining.
        </p>
        <p>
         In advanced cases of IPH, the lungs macroscopically have a striking brown appearance due to hemosiderosis and varying degrees of consolidation and fibrosis. Localized interstitial fibrosis with collagen deposition is a prominent feature in patients with long-standing disease [
         <a href="#rid2">
          2-4,8,10,14
         </a>
         ].
        </p>
        <p>
         While not commonly performed, electron microscopy demonstrates swollen, vacuolated alveolar endothelial cells [
         <a href="#rid2">
          2
         </a>
         ]. The basement membrane of the alveolar capillaries may be focally thickened; localized discontinuities with rupture of the membrane have also been inconsistently described [
         <a href="#rid2">
          2,3,5,10
         </a>
         ]. Absence of electron-dense material along the basement membrane is evidence against immune complex deposition [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of IPH largely relies on demonstration of alveolar hemorrhage and exclusion of other disorders in which diffuse alveolar hemorrhage (DAH) is a cardinal sign  (
         <a class="graphic graphic_table graphicRef52374" href="/z/d/graphic/52374.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef119265" href="/z/d/graphic/119265.html" rel="external">
          algorithm 1
         </a>
         ), because there is no feature that is pathognomonic for IPH [
         <a href="#rid1">
          1,63
         </a>
         ]. The diagnosis of IPH is supported by the combination of compatible clinical findings (eg, hemoptysis, cough, dyspnea), compatible test results (eg, opacities on chest radiograph, iron deficiency anemia, negative serologic tests for rheumatic and immune-mediated diseases), and the presence of hemosiderin-laden alveolar macrophages on bronchoalveolar lavage (BAL) and lung biopsy specimens.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In children, a confident clinical diagnosis can be made with a clinical presentation, laboratory testing, high resolution computed tomography (HRCT) pattern, and BAL findings that are typical for IPH, negative serology for immune-mediated diseases, and positive testing for celiac disease [
         <a href="#rid20">
          20-22,45
         </a>
         ]. Transbronchial or thoracoscopic lung biopsy are typically deferred unless the patient does not respond to therapy or celiac disease is excluded. (See
         <a class="local">
          'Laboratory testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In adults, lung biopsy is often needed to fully exclude other causes of alveolar hemorrhage  (
         <a class="graphic graphic_table graphicRef52374" href="/z/d/graphic/52374.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="local">
          'Bronchoscopy'
         </a>
         above and
         <a class="local">
          'Lung biopsy'
         </a>
         above). Lung biopsies should not reveal any other specific pathology, such as vasculitis/capillaritis, deposition of immunoglobulins, granulomas (indicate mycobacterial infection, sarcoidosis, or granulomatosis with polyangiitis), or other evidence of infection. (See
         <a class="local">
          'Histopathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to light microscopy, biopsy specimens, preferably frozen, should be examined with immunofluorescence technique using a panel of antibodies against immunoglobulins and complement fractions in order to search for immune complexes. The finding of immune complex deposition would argue against the diagnosis of IPH. (See
         <a class="local">
          'Histopathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Lane-Hamilton syndrome (association of IPH and celiac disease) is reported in adults, so an evaluation for celiac disease is appropriate, if not already performed. (See
         <a class="local">
          'Laboratory testing'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4771.html" rel="external">
          "Diagnosis of celiac disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2421208260">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of initial and recurrent episodes of alveolar hemorrhage is broad and includes infectious causes, rheumatic diseases, immune-mediated diseases, drug-induced lung toxicity, thromboembolic disease, bleeding disorders, and a variety of neoplasms  (
         <a class="graphic graphic_table graphicRef52374" href="/z/d/graphic/52374.html" rel="external">
          table 1
         </a>
         ). Causes of diffuse alveolar hemorrhage (DAH) in children and adults are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6370.html" rel="external">
          "Hemoptysis in children", section on 'Causes of hemoptysis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection
         </strong>
         – A broad spectrum of lung infections are associated with alveolar hemorrhage, usually in the setting of acute respiratory distress syndrome, including severe bacterial pneumonia (eg,
         <em>
          Streptococcus pneumoniae
         </em>
         ,
         <em>
          Legionella pneumophila
         </em>
         ,
         <em>
          Staphylococcus aureus
         </em>
         ), viral pneumonia (particularly influenza A), leptospirosis, and
         <em>
          Pneumocystic jirovecii
         </em>
         pneumonia. (See
         <a class="medical medical_review" href="/z/d/html/1609.html" rel="external">
          "Acute respiratory distress syndrome: Epidemiology, pathophysiology, pathology, and etiology in adults", section on 'Pneumonia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5973.html" rel="external">
          "Seasonal influenza in children: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">
          "Seasonal influenza in adults: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5527.html" rel="external">
          "Leptospirosis: Epidemiology, microbiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Infectious etiologies can usually be excluded by the testing described above (see
         <a class="local">
          'Evaluation'
         </a>
         above), with particular attention to community-acquired infections (eg, influenza, coronavirus disease 2019 [COVID-19]), exposures (eg, contaminated water, birds, farm animals, mice, rabbits) and underlying immune compromise. A spectrum of microbiologic studies can be performed on bronchoalveolar lavage (BAL) samples, depending on the clinical setting. (See
         <a class="medical medical_review" href="/z/d/html/4303.html" rel="external">
          "Basic principles and technique of bronchoalveolar lavage", section on 'Microbiologic analysis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rheumatic diseases
         </strong>
         – Rheumatic diseases associated with alveolar hemorrhage include systemic lupus erythematosus, antiphospholipid (APL) antibody syndrome, granulomatosis with polyangiitis, microscopic polyangiitis, anti-glomerular basement membrane (GBM) antibody (Goodpasture) disease, and mixed cryoglobulinemia. Often the extrapulmonary and serologic manifestations of these diseases will guide the diagnosis (eg, renal or cutaneous involvement), but virtually all patients with DAH should be evaluated for these processes [
         <a href="#rid64">
          64
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">
          "Pulmonary manifestations of systemic lupus erythematosus in adults", section on 'Pulmonary hemorrhage'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4330.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Respiratory tract involvement"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3108.html" rel="external">
          "Anti-GBM (Goodpasture) disease: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4678.html" rel="external">
          "Diagnosis of antiphospholipid syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3062.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thoracic endometriosis
         </strong>
         – Thoracic endometriosis involving the lung parenchyma can cause recurrent catamenial hemoptysis, although bleeding is usually minor. (See
         <a class="medical medical_review" href="/z/d/html/6687.html" rel="external">
          "Clinical features, diagnostic approach, and treatment of adults with thoracic endometriosis", section on 'Hemoptysis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medications
         </strong>
         – A number of medications are associated with alveolar hemorrhage, and use of these agents should be carefully sought. The mechanisms of DAH vary among the different agents and include acute lung toxicity with diffuse alveolar damage (
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">
          penicillamine
         </a>
         ), drug-induced lupus (penicillamine), drug-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (
         <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">
          methimazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">
          propylthiouracil
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes", section on 'Drug-induced diffuse alveolar hemorrhage'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">
          "Drug-induced lupus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inhalational exposures
         </strong>
         – Inhalational exposures that have been associated with alveolar hemorrhage include crack cocaine (possibly related to ANCA-associated vasculitis induced by the cutting agent levamisole) and trimellitic anhydride, which is used in the manufacture of resins, paints, and plastic. A careful history can be used to exclude these possibilities. (See
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes", section on 'Clues to a specific etiology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         IPH is a rare condition that does not lend itself to controlled treatment trials. As a result, therapy is based upon reported experiences in individual cases or small case series [
         <a href="#rid8">
          8,47,65-68
         </a>
         ]. Systemic glucocorticoids are the mainstay of therapy for acute alveolar hemorrhage [
         <a href="#rid68">
          68
         </a>
         ]. For patients with concomitant celiac disease, a gluten-free diet may prevent recurrent episodes; for most other patients, chronic suppression can be achieved with a low dose of oral glucocorticoids, although some patients require additional immunosuppressive agents.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Acute alveolar hemorrhage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with acute alveolar hemorrhage due to IPH will receive initial empiric antibiotics until infection has been confidently excluded.
        </p>
        <p class="headingAnchor" id="H1742447980">
         <span class="h3">
          Supportive care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with acute alveolar hemorrhage due to IPH often have hypoxemia requiring supplemental oxygen.
        </p>
        <p class="headingAnchor" id="H472561572">
         <span class="h3">
          Systemic glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic glucocorticoids are the mainstay of therapy for acute alveolar hemorrhage due to IPH. The use of systemic glucocorticoids for IPH grew out of the impression of an immune pathogenesis. Case reports and case series suggest that systemic glucocorticoids reduce the morbidity and mortality of acute episodes of alveolar bleeding [
         <a href="#rid1">
          1,8,10,47,65-71
         </a>
         ].
        </p>
        <p>
         For the treatment of acute episodes of alveolar hemorrhage without respiratory failure, we suggest induction treatment with an initial dose of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         0.5 to 0.75 mg/kg per day (up to 60 mg/day). Induction treatment should continue until pulmonary bleeding has stopped and the chest radiograph shows partial or complete regression of newly acquired opacifications, which usually requires four to eight weeks. At this point, prednisone or prednisolone should be tapered by 5 mg every other week to a maintenance dose of 10 to 15 mg/day.
        </p>
        <p class="headingAnchor" id="H3762466840">
         <span class="h2">
          Respiratory failure due to alveolar hemorrhage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients present with respiratory failure due to severe alveolar hemorrhage. These patients require prompt attention to immunosuppressive therapy. While formal studies are lacking, we suggest using combined therapy with high-dose glucocorticoids and a second immunosuppressive agent in these severely ill patients, as this approach has been beneficial in patients with other immunologic causes of diffuse alveolar hemorrhage (DAH). (See
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes", section on 'Additional immunosuppressive therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3813186434">
         <span class="h3">
          Ventilatory support
         </span>
         <span class="headingEndMark">
          —
         </span>
         When alveolar hemorrhage is widespread, patients can develop hypoxemic respiratory failure that requires noninvasive or invasive mechanical ventilation. The implementation of noninvasive or invasive mechanical ventilation for acute respiratory failure is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/109649.html" rel="external">
          "Initiating mechanical ventilation in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1641.html" rel="external">
          "Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">
          "Acute respiratory distress syndrome: Ventilator management strategies for adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1636.html" rel="external">
          "Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H745694113">
         <span class="h3">
          High-dose glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         For adults with respiratory failure due to severe alveolar hemorrhage, we suggest intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         in a pulse dose, 500 to 2000 mg per day (in divided doses) for up to five days, based on its use for other immunologic causes of DAH [
         <a href="#rid66">
          66
         </a>
         ]. In children, pulse dose methylprednisolone dosing is typically 20 mg/kg per day, intravenously. (See
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes", section on 'Glucocorticoids'
         </a>
         .)
        </p>
        <p>
         Once the patient has stabilized, the glucocorticoid is transitioned to an oral preparation (eg, equivalent of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         0.5 to 1 mg/kg per day) with gradual tapering to a maintenance dose [
         <a href="#rid45">
          45,72
         </a>
         ]. (See
         <a class="local">
          'Glucocorticoids'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3984480123">
         <span class="h3">
          Immunosuppressive agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         A few case reports describe the use of an immunosuppressive agent in addition to oral glucocorticoids in the setting of respiratory failure. Examples include
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         [
         <a href="#rid73">
          73,74
         </a>
         ],
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         [
         <a href="#rid45">
          45,74
         </a>
         ],
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         [
         <a href="#rid74">
          74
         </a>
         ],
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         , and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         [
         <a href="#rid68">
          68
         </a>
         ]. The decision about which specific immunosuppressive agent to select depends on the anticipated responsiveness to glucocorticoids, age of the patient, severity of illness, and clinician familiarity with the individual agents; the optimal indications, dosing, and duration of therapy have not been determined. (See
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes", section on 'Additional immunosuppressive therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1665046701">
         <span class="h3">
          Extracorporeal membrane oxygenation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extracorporeal membrane oxygenation (ECMO) may be able to support the rare patient who develops intractable hypoxemia due to acute alveolar hemorrhage [
         <a href="#rid70">
          70,75
         </a>
         ]. ECMO has also been used to support patients through DAH from other causes. In separate reports, two children with IPH and respiratory failure due to severe pulmonary hemorrhage were supported with ECMO until immunosuppressive therapy controlled the hemorrhage [
         <a href="#rid70">
          70,75
         </a>
         ]. The use of ECMO is limited to centers with specialized expertise. (See
         <a class="medical medical_review" href="/z/d/html/1625.html" rel="external">
          "Extracorporeal life support in adults in the intensive care unit: Overview"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Prevention of recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         For untreated patients, IPH is characterized by recurrent episodes of alveolar hemorrhage over many years and a portion of these patients will develop fibrotic lung disease due to recurrent hemorrhage. Thus, efforts to prevent recurrent hemorrhage are indicated. For patients with concomitant celiac disease, a gluten-free diet may be sufficient to stop further episodes. For patients without celiac disease, we suggest chronic suppressive therapy with oral glucocorticoids. The optimal dose and duration has not been determined. Additional immunosuppressive therapy is occasionally needed.
        </p>
        <p>
         While data in support of an association between IPH and cow’s milk allergy are conflicting, if there is suspicion or evidence of allergy to cow’s milk, this nutrient should be excluded from the diet to observe whether it might have a positive effect on the disease.
        </p>
        <p class="headingAnchor" id="H4145134960">
         <span class="h3">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many patients with IPH appear to respond favorably to chronic oral glucocorticoids, with decreased frequency of episodes of acute alveolar hemorrhage and a delay in or arrest of fibrotic changes [
         <a href="#rid8">
          8,10,66,69
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose and duration
         </strong>
         – The optimal dose and duration of oral glucocorticoids to prevent recurrences of alveolar hemorrhage has not been determined. After the initial treatment with high-dose glucocorticoids described above, we taper
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (or equivalent) to 10 to 15 mg/day. In general, if the patient is free of recurrent events for 18 to 24 months, we further taper and discontinue prednisone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In children, if there is recurrence of bleeding after tapering, treatment should be resumed and continued for another 24 to 36 months before tapering is tried again. If there is still recurrence after the second treatment period, long-term treatment should be considered at least until adult age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In adults, the recurrence rate is generally lower than in children and tapering is reasonable after 12 to 18 months without any recurrences. The longer the recurrence free period, the less likely the patient will have recurrence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         During chronic glucocorticoid therapy, patients should be monitored appropriately for side effects. Infectious complications, including
         <em>
          Legionella pneumonia
         </em>
         and fatal invasive pulmonary aspergillosis, have been reported in patients with IPH receiving glucocorticoids or other immunosuppressive agents [
         <a href="#rid76">
          76,77
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The survival rate of IPH has improved significantly with glucocorticoid treatment [
         <a href="#rid68">
          68
         </a>
         ]. In a series of 23 children with IPH, low-dose oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         was associated with prolonged survival (one death in 2 to 14 years of monitoring) compared with historical controls [
         <a href="#rid47">
          47,66
         </a>
         ]. In another series of 17 patients, long-term glucocorticoid therapy was associated with a five-year Kaplan-Meier survival of 86 percent [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          Immunosuppressive drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         An immunosuppressive agent may be added to initial oral glucocorticoid therapy in patients who have recurrent episodes of hemorrhage that limit tapering of oral glucocorticoids. However, evidence supporting the efficacy of this approach is limited. In a physician survey, agents used in addition to glucocorticoids for maintenance therapy of IPH included
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         (64 percent),
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         (37 percent), and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (16 percent) [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
         Separately, a number of reports describe successful use of
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         or
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         in combination with oral glucocorticoids for maintenance therapy [
         <a href="#rid1">
          1,4,31,45,74,78-80
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7994.html" rel="external">
          "Pharmacology and side effects of azathioprine when used in rheumatic diseases"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">
          "Antimalarial drugs in the treatment of rheumatic disease"
         </a>
         .)
        </p>
        <p>
         Other immunosuppressive drugs, such as
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">
          6-mercaptopurine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , or
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         [
         <a href="#rid68">
          68
         </a>
         ], are occasionally employed in patients with a particularly severe presentation or an inadequate response to glucocorticoids, but their efficacy is also not well established [
         <a href="#rid73">
          73,74,81-83
         </a>
         ]. Maintenance therapy aiming for a glucocorticoid-sparing effect has been reported with 6-mercaptopurine in a small number of patients, although recurrences requiring dose adjustment were noted. (See
         <a class="medical medical_review" href="/z/d/html/7963.html" rel="external">
          "General principles of the use of cyclophosphamide in rheumatic diseases"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4056.html" rel="external">
          "Overview of azathioprine and mercaptopurine use in inflammatory bowel disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H830950261">
         <span class="h3">
          Treatment of concomitant celiac disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with evidence of concomitant celiac disease should follow a gluten-free diet as treatment for their celiac disease. A gluten-free diet will often prevent recurrent episodes of alveolar hemorrhage and enable the patient to avoid the potential adverse effects of an alternative treatment with long-term glucocorticoids [
         <a href="#rid14">
          14-23
         </a>
         ]. The diagnosis and management of celiac disease are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/100553.html" rel="external">
          "Diagnosis of celiac disease in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5907.html" rel="external">
          "Management of celiac disease in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4771.html" rel="external">
          "Diagnosis of celiac disease in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4777.html" rel="external">
          "Management of celiac disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Lung transplantation for advanced fibrosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Single lung transplantation has been reported, but disease recurrence within the allograft appears to be a problem [
         <a href="#rid71">
          71,84
         </a>
         ]. In one report, a 24-year-old woman with pulmonary insufficiency due to IPH developed graft failure of the single left lung allograft, and retransplantation was performed after nine months [
         <a href="#rid71">
          71
         </a>
         ]. The patient succumbed to respiratory failure three months after the second transplantation. Autopsy showed no evidence of infection or rejection, but did reveal findings compatible with IPH in the transplanted lungs. In another report, IPH recurred three years after bilateral lung transplantation [
         <a href="#rid84">
          84
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">
          "Lung transplantation: General guidelines for recipient selection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1258019527">
         <span class="h1">
          MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on clinical experience, the most useful parameters to follow for assessing whether a patient is having a beneficial response to therapy include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Frequency and intensity of hemoptysis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regression of iron deficiency anemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improvement in chest radiograph opacities
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulse oxygen saturation by oximetry, at rest and during six-minute walk test
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffusing capacity for carbon monoxide (DLCO)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2193260385">
         <span class="h1">
          FUTURE DIRECTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alternative preparations for delivery of systemic glucocorticoids have been assessed in IPH. As an example, liposteroid [
         <a href="#rid85">
          85
         </a>
         ] (a preparation of
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         palmitate in lipid microspheres not available in the United States) 0.8 mg/kg per day, administered intravenously for three consecutive days was effective in a series of nine children with acute presentation of IPH [
         <a href="#rid86">
          86
         </a>
         ]. Monthly intravenous infusion of liposteroid dexamethasone palmitate 0.8 mg/kg was effective as maintenance therapy in patients who had recurrent alveolar hemorrhage despite oral glucocorticoid therapy [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
         High-dose inhaled glucocorticoids may be an alternative to oral glucocorticoids after initial stabilization with oral glucocorticoid [
         <a href="#rid45">
          45,87,88
         </a>
         ]. Inhaled glucocorticoid treatment was assessed in an observational study in 26 children whose IPH was treated with an initial course of
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         and
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         : 17 patients had no recurrence, 5 patients had a recurrence requiring a course of prednisolone, and 4 patients had frequent recurrences and were treated with chronic prednisolone and
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         [
         <a href="#rid45">
          45
         </a>
         ]. Additional study is needed to determine the safety of this approach.
        </p>
        <p>
         Individual case reports describe success with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         and intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis of IPH is difficult to assess because of the small series of patients, short observation times, and incomplete follow-up. The two most frequent causes of death are acute respiratory failure due to copious and diffuse pulmonary hemorrhage and chronic respiratory failure due to pulmonary hemosiderosis and fibrosis [
         <a href="#rid6">
          6,47,65
         </a>
         ].
        </p>
        <p>
         Survival times vary widely [
         <a href="#rid8">
          8,32,33,47,69
         </a>
         ]. As an example, one series of 17 pediatric patients documented a five-year survival rate of 86 percent [
         <a href="#rid69">
          69
         </a>
         ]. A separate series of 25 children reported disease control in 23 (92 percent) at 5.5 years, progressive pulmonary fibrosis in one and death due to pulmonary hemorrhage in another [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         In adults, the course is often prolonged, symptoms are less pronounced, and the prognosis may be more favorable, although data are limited [
         <a href="#rid8">
          8,33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Idiopathic pulmonary hemosiderosis (IPH) is a rare clinical entity of unknown etiology, characterized by recurrent episodes of diffuse alveolar hemorrhage (DAH) and often presenting with hemoptysis. Iron deficiency anemia may develop due to sequestration of red cell hemoglobin iron to hemosiderin iron in the alveolar macrophages. Deposition of abundant hemosiderin iron in the lungs can lead to pulmonary fibrosis. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above and
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coexistence of celiac disease has been reported in patients with IPH (Lane-Hamilton syndrome) and provides support for a potential immunologic mechanism. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clinical presentation of IPH varies from an acute illness with hemoptysis and dyspnea to an insidious process characterized by fatigue, anemia, and slowly progressive exertional dyspnea. Occasionally, iron deficiency anemia is the presenting manifestation. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The evaluation of suspected IPH follows steps to assess the severity of respiratory impairment and anemia, confirm alveolar hemorrhage, and narrow the broad differential diagnosis of DAH  (
         <a class="graphic graphic_table graphicRef52374" href="/z/d/graphic/52374.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef119265" href="/z/d/graphic/119265.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         During an acute episode, the chest radiograph and high resolution computed tomography (HRCT) demonstrate ground glass opacities that are often bilateral. Examination of sputum (when available) and bronchoalveolar lavage (BAL) fluid reveals hemosiderin-laden alveolar macrophages. (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The diagnosis of IPH largely relies on demonstration of alveolar hemorrhage and exclusion of other disorders in which DAH is a cardinal sign  (
         <a class="graphic graphic_table graphicRef52374" href="/z/d/graphic/52374.html" rel="external">
          table 1
         </a>
         ), as no feature is pathognomonic. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In children, a confident clinical diagnosis can be made in patients with DAH, negative serology for immune-mediated diseases, and positive testing for celiac disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In adults, the diagnosis of IPH requires lung biopsy documentation of large numbers of hemosiderin-laden macrophages in the alveoli, without evidence of vasculitis, capillaritis, infection, granulomas, or deposition of immunoglobulins in any specific pattern. (See
         <a class="local">
          'Histopathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For the treatment of acute episodes of alveolar hemorrhage related to IPH, we suggest systemic glucocorticoid therapy (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The typical initial dose is oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         0.5 to 0.75 mg/kg per day (up to 60 mg/day), or the equivalent dose intravenously. (See
         <a class="local">
          'Systemic glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For adults with impending or actual respiratory failure due to acute alveolar hemorrhage, we typically use a higher dose of
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         (eg, 500 to 2000 mg/day in divided doses, intravenously for up to five days. For children in this setting, the usual pulse dose of methylprednisolone is 20 mg/kg per day. (See
         <a class="local">
          'High-dose glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         After resolution of the acute episode of alveolar hemorrhage, oral glucocorticoids are gradually tapered to the equivalent of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         10 to 15 mg/day, as tolerated. In the absence of recurrences over 12 to 18 months in adults and 18 to 24 months in children, we further taper and discontinue prednisone. (See
         <a class="local">
          'Prevention of recurrence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who have severe initial disease or have recurrent episodes of alveolar hemorrhage that limit tapering of systemic glucocorticoid, we suggest using a combination of systemic glucocorticoids with another immunosuppressive agent (eg,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">
          6-mercaptopurine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , or
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Immunosuppressive agents'
         </a>
         above and
         <a class="local">
          'Immunosuppressive drugs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A gluten-free diet may prevent recurrent episodes of alveolar hemorrhage in patients with coexistent celiac disease. (See
         <a class="local">
          'Treatment of concomitant celiac disease'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4777.html" rel="external">
          "Management of celiac disease in adults"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ioachimescu OC, Sieber S, Kotch A. Idiopathic pulmonary haemosiderosis revisited. Eur Respir J 2004; 24:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corrin B, Jagusch M, Dewar A, et al. Fine structural changes in idiopathic pulmonary haemosiderosis. J Pathol 1987; 153:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donald KJ, Edwards RL, McEvoy JD. Alveolar capillary basement membrane lesions in Goodpasture's syndrome and idiopathic pulmonary hemosiderosis. Am J Med 1975; 59:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeager H Jr, Powell D, Weinberg RM, et al. Idiopathic pulmonary hemosiderosis: ultrastructural studies and responses to azathioprine. Arch Intern Med 1976; 136:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyatt RW, Adelstein ER, Halazun JF, Lukens JN. Ultrastructure of the lung in idiopthic pulmonary hemosiderosis. Am J Med 1972; 52:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen S. Idiopathic pulmonary hemosiderosis. Am J Med Sci 1999; 317:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanco A, Solís P, Gómez S, et al. C1q-binding immune complexes and other immunological studies in children with pulmonary hemosiderosis. Allergol Immunopathol (Madr) 1984; 12:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ali AM, Milman N, Clausen PP, et al. Idiopathic pulmonary haemosiderosis. Favourable effect of corticosteroids in two women aged 16 and 55 years. Eur Respir Topic 1998; 4:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dolan CJ Jr, Srodes CH, Duffy FD. Idiopathic pulmonary hemosiderosis. Electron microscopic, immunofluorescent, and iron kinetic studies. Chest 1975; 68:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irwin RS, Cottrell TS, Hsu KC, et al. Idiopathic pulmonary hemosiderosis: an electron microscopic and immunofluorescent study. Chest 1974; 65:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saha BK, Bonnier A, Chenna P, Milman NT. Prevalence of autoantibodies in pediatric patients with idiopathic pulmonary hemosiderosis: a scoping review of the literature in the period 1980-2021. Clin Rheumatol 2022; 41:977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Clainche L, Le Bourgeois M, Fauroux B, et al. Long-term outcome of idiopathic pulmonary hemosiderosis in children. Medicine (Baltimore) 2000; 79:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stainer A, Rice A, Devaraj A, et al. Diffuse alveolar haemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults. BMC Pulm Med 2019; 19:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright PH, Menzies IS, Pounder RE, Keeling PW. Adult idiopathic pulmonary haemosiderosis and coeliac disease. Q J Med 1981; 50:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pacheco A, Casanova C, Fogue L, Sueiro A. Long-term clinical follow-up of adult idiopathic pulmonary hemosiderosis and celiac disease. Chest 1991; 99:1525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hemoptysis, pulmonary infiltrates, and diarrhea in a 36-year-old man. Am J Med 1986; 80:930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reading R, Watson JG, Platt JW, Bird AG. Pulmonary haemosiderosis and gluten. Arch Dis Child 1987; 62:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouros D, Panagou P, Rokkas T, Siafakas NM. Bronchoalveolar lavage findings in a young adult with idiopathic pulmonary haemosiderosis and coeliac disease. Eur Respir J 1994; 7:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal R, Aggarwal AN, Gupta D. Lane-Hamilton syndrome: simultaneous occurrence of coeliac disease and idiopathic pulmonary haemosiderosis. Intern Med J 2007; 37:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khemiri M, Ouederni M, Khaldi F, Barsaoui S. Screening for celiac disease in idiopathic pulmonary hemosiderosis. Gastroenterol Clin Biol 2008; 32:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane DJ, Hamilton WS. Idiopathic steatorrhoea and idiopathic pulmonary haemosiderosis. Br Med J 1971; 2:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sethi GR, Singhal KK, Puri AS, Mantan M. Benefit of gluten-free diet in idiopathic pulmonary hemosiderosis in association with celiac disease. Pediatr Pulmonol 2011; 46:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milman N, Pedersen FM. Idiopathic pulmonary haemosiderosis. Epidemiology, pathogenic aspects and diagnosis. Respir Med 1998; 92:902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boat TF, Polmar SH, Whitman V, et al. Hyperreactivity to cow milk in young children with pulmonary hemosiderosis and cor pulmonale secondary to nasopharyngeal obstruction. J Pediatr 1975; 87:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torres MJ, Girón MD, Corzo JL, et al. Release of inflammatory mediators after cow's milk intake in a newborn with idiopathic pulmonary hemosiderosis. J Allergy Clin Immunol 1996; 98:1120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Custer G, Balcerzak S, Rinehart J. Human macrophage hemoglobin-iron metabolism in vitro. Am J Hematol 1982; 13:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeGowin RL, Sorensen LB, Charleston DB, et al. Retention of radioiron in the lungs of a woman with idiopathic pulmonary hemosiderosis. Ann Intern Med 1968; 69:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fillet G, Beguin Y, Baldelli L. Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood 1989; 74:844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grigg J, Cooke MS, Panickar JR. Case 3-2007: a boy with respiratory insufficiency. N Engl J Med 2007; 356:2329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Persson HL, Vainikka LK, Eriksson HB, Wennerström U. Lane-Hamilton syndrome: ferritin protects lung macrophages against iron and oxidation. Chest 2011; 139:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yao TC, Hung IJ, Wong KS, et al. Idiopathic pulmonary haemosiderosis: an Oriental experience. J Paediatr Child Health 2003; 39:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taytard J, Nathan N, de Blic J, et al. New insights into pediatric idiopathic pulmonary hemosiderosis: the French RespiRare(®) cohort. Orphanet J Rare Dis 2013; 8:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen XY, Sun JM, Huang XJ. Idiopathic pulmonary hemosiderosis in adults: review of cases reported in the latest 15 years. Clin Respir J 2017; 11:677.
          </a>
         </li>
         <li class="breakAll">
          Lara AR, Frankel SK, Schwarz MI. Diffuse alveolar hemorrhage. In: Interstitial Lung Disease, 5th, Schwarz MI, King TE Jr (Eds), People's Medical Publishing House, Shelton CT 2011. p.805.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beckerman RC, Taussig LM, Pinnas JL. Familial idiopathic pulmonary hemosiderosis. Am J Dis Child 1979; 133:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thaell JF, Greipp PR, Stubbs SE, Siegal GP. Idiopathic pulmonary hemosiderosis: two cases in a family. Mayo Clin Proc 1978; 53:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassimos CD, Chryssanthopoulos C, Panagiotidou C. Epidemiologic observations in idiopathic pulmonary hemosiderosis. J Pediatr 1983; 102:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dearborn DG, Yike I, Sorenson WG, et al. Overview of investigations into pulmonary hemorrhage among infants in Cleveland, Ohio. Environ Health Perspect 1999; 107 Suppl 3:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hossain MA, Ahmed MS, Ghannoum MA. Attributes of Stachybotrys chartarum and its association with human disease. J Allergy Clin Immunol 2004; 113:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown CM, Redd SC, Damon SA, Centers for Disease Control and Prevention (CDC). Acute idiopathic pulmonary hemorrhage among infants. Recommendations from the Working Group for Investigation and Surveillance. MMWR Recomm Rep 2004; 53:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dearborn DG, Smith PG, Dahms BB, et al. Clinical profile of 30 infants with acute pulmonary hemorrhage in Cleveland. Pediatrics 2002; 110:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alimi A, Taytard J, Abou Taam R, et al. Pulmonary hemosiderosis in children with Down syndrome: a national experience. Orphanet J Rare Dis 2018; 13:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis AE, Høi-Hansen CE, Buchvald F, Petersen W. [Idiopathic pulmonary haemosiderosis in a one-year-old girl with Down syndrome]. Ugeskr Laeger 2014; 176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watanabe H, Ayusawa M, Kato M, et al. Idiopathic pulmonary hemosiderosis complicated by Down syndrome. Pediatr Int 2015; 57:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kabra SK, Bhargava S, Lodha R, et al. Idiopathic pulmonary hemosiderosis: clinical profile and follow up of 26 children. Indian Pediatr 2007; 44:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen RL, Chuang SS. Silent idiopathic pulmonary hemosiderosis with iron-deficiency anemia but normal serum ferritin. J Pediatr Hematol Oncol 2007; 29:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soergel, KH, Sommers, SC. Idiopathic pulmonary hemosiderosis and related syndromes. Am J Med 1962; 32:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgan PG, Turner-Warwick M. Pulmonary haemosiderosis and pulmonary haemorrhage. Br J Dis Chest 1981; 75:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walters GO, Miller FM, Worwood M. Serum ferritin concentration and iron stores in normal subjects. J Clin Pathol 1973; 26:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milman N, Pedersen NS, Visfeldt J. Serum ferritin in healthy Danes: relation to marrow haemosiderin iron stores. Dan Med Bull 1983; 30:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khorashadi L, Wu CC, Betancourt SL, Carter BW. Idiopathic pulmonary haemosiderosis: spectrum of thoracic imaging findings in the adult patient. Clin Radiol 2015; 70:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harte S, McNicholas WT, Donnelly SC, Dodd JD. Honeycomb cysts in idiopathic pulmonary haemosiderosis: high-resolution CT appearances in two adults. Br J Radiol 2008; 81:e295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allue X, Wise MB, Beaudry PH. Pulmonary function studies in idiopathic pulmonary hemosiderosis in children. Am Rev Respir Dis 1973; 107:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ewan PW, Jones HA, Rhodes CG, Hughes JM. Detection of intrapulmonary hemorrhage with carbon monoxide uptake. Application in goodpasture's syndrome. N Engl J Med 1976; 295:1391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kocakoc E, Kiris A, Sen Y, Bozgeyik Z. Pediatric idiopathic pulmonary hemosiderosis diagnosed by sputum analysis: plain radiography and computed tomography findings. Med Princ Pract 2003; 12:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visner GA, Faro A, Zander DS. Role of transbronchial biopsies in pediatric lung diseases. Chest 2004; 126:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayes D Jr, Baker PB, Kopp BT, et al. Surveillance transbronchial biopsies in infant lung and heart-lung transplant recipients. Pediatr Transplant 2013; 17:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharp C, McCabe M, Adamali H, Medford AR. Use of transbronchial cryobiopsy in the diagnosis of interstitial lung disease-a systematic review and cost analysis. QJM 2017; 110:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hetzel J, Eberhardt R, Petermann C, et al. Bleeding risk of transbronchial cryobiopsy compared to transbronchial forceps biopsy in interstitial lung disease - a prospective, randomized, multicentre cross-over trial. Respir Res 2019; 20:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soergel, KH, Sommers, SC. The alveolar epithelial lesion of idiopathic pulmonary hemosiderosis. Am Rev Respir Dis 1962; 85:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green RJ, Ruoss SJ, Kraft SA, et al. Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management. Chest 1996; 110:1305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jennings CA, King TE Jr, Tuder R, et al. Diffuse alveolar hemorrhage with underlying isolated, pauciimmune pulmonary capillaritis. Am J Respir Crit Care Med 1997; 155:1101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yao TC, Hung IJ, Jaing TH, Yang CP. Pitfalls in the diagnosis of idiopathic pulmonary haemosiderosis. Arch Dis Child 2002; 86:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saha BK, Chong WH, Milman NT. Differentiation of idiopathic pulmonary hemosiderosis from rheumatologic and autoimmune diseases causing diffuse alveolar hemorrhage: establishing a diagnostic approach. Clin Rheumatol 2022; 41:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen VR, Valerius NH. [Idiopathic pulmonary hemosiderosis. A cause of severe iron deficiency anemia in childhood]. Ugeskr Laeger 1995; 157:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiper N, Göçmen A, Ozçelik U, et al. Long-term clinical course of patients with idiopathic pulmonary hemosiderosis (1979-1994): prolonged survival with low-dose corticosteroid therapy. Pediatr Pulmonol 1999; 27:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohga S, Nomura A, Suga N, et al. Liposteroid against refractory pulmonary haemorrhage in idiopathic pulmonary haemosiderosis. Eur J Pediatr 1994; 153:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saha BK, Milman NT. Idiopathic pulmonary hemosiderosis: a review of the treatments used during the past 30 years and future directions. Clin Rheumatol 2021; 40:2547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saeed MM, Woo MS, MacLaughlin EF, et al. Prognosis in pediatric idiopathic pulmonary hemosiderosis. Chest 1999; 116:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun LC, Tseng YR, Huang SC, et al. Extracorporeal membrane oxygenation to rescue profound pulmonary hemorrhage due to idiopathic pulmonary hemosiderosis in a child. Pediatr Pulmonol 2006; 41:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wroblewski BM, Stefanovic CR, McDonough VM, Kidik PJ. The challenges of idiopathic pulmonary hemosiderosis and lung transplantation. Crit Care Nurse 1997; 17:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castellazzi L, Patria MF, Frati G, et al. Idiopathic pulmonary haemosiderosis in paediatric patients: how to make an early diagnosis. Ital J Pediatr 2016; 42:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naithani R, Chandra J, Singh V, et al. Life threatening exacerbation in idiopathic pulmonary hemosiderosis salvaged by cyclophosphamide infusion. Indian J Chest Dis Allied Sci 2006; 48:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chin CI, Kohn SL, Keens TG, et al. A physician survey reveals differences in management of idiopathic pulmonary hemosiderosis. Orphanet J Rare Dis 2015; 10:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutierrez S, Shaw S, Huseni S, et al. Extracorporeal life support for a 5-week-old infant with idiopathic pulmonary hemosiderosis. Eur J Pediatr 2014; 173:1573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watson AM, Boyce TG, Wylam ME. Legionella pneumonia: infection during immunosuppressive therapy for idiopathic pulmonary hemosiderosis. Pediatr Infect Dis J 2004; 23:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helman DL, Sullivan A, Kariya ST, et al. Management of idiopathic pulmonary haemosiderosis in pregnancy: report of two cases. Respirology 2003; 8:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossi GA, Balzano E, Battistini E, et al. Long-term prednisone and azathioprine treatment of a patient with idiopathic pulmonary hemosiderosis. Pediatr Pulmonol 1992; 13:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrd RB, Gracey DR. Immunosuppressive treatment of idiopathic pulmonary hemosiderosis. JAMA 1973; 226:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Airaghi L, Ciceri L, Giannini S, et al. Idiopathic pulmonary hemosiderosis in an adult. Favourable response to azathioprine. Monaldi Arch Chest Dis 2001; 56:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang SH, Lee PY, Niu CK. Treatment of pediatric idiopathic pulmonary hemosiderosis with low-dose cyclophosphamide. Ann Pharmacother 2003; 37:1618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo XQ, Ke ZY, Huang LB, et al. Maintenance therapy with dose-adjusted 6-mercaptopurine in idiopathic pulmonary hemosiderosis. Pediatr Pulmonol 2008; 43:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flanagan F, Glackin L, Slattery DM. Successful treatment of idiopathic pulmonary capillaritis with intravenous cyclophosphamide. Pediatr Pulmonol 2013; 48:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calabrese F, Giacometti C, Rea F, et al. Recurrence of idiopathic pulmonary hemosiderosis in a young adult patient after bilateral single-lung transplantation. Transplantation 2002; 74:1643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saha BK, Milman NT. Short Review of Liposteroid: A Novel Targeted Glucocorticoid Preparation for Treatment of Autoimmune and Inflammatory Diseases. Prague Med Rep 2021; 122:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doi T, Ohga S, Ishimura M, et al. Long-term liposteroid therapy for idiopathic pulmonary hemosiderosis. Eur J Pediatr 2013; 172:1475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elinder G. Budesonide inhalation to treat idiopathic pulmonary haemosiderosis. Lancet 1985; 1:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tutor JD, Eid NS. Treatment of idiopathic pulmonary hemosiderosis with inhaled flunisolide. South Med J 1995; 88:984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Picard E, Goldberg S, Izbicki G, Kerem E. Sequential pulmonary function measurements in an infant treated with idiopathic pulmonary hemosiderosis. Isr Med Assoc J 2008; 10:590.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4318 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15293620" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Idiopathic pulmonary haemosiderosis revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3430232" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Fine structural changes in idiopathic pulmonary haemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1106191" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Alveolar capillary basement membrane lesions in Goodpasture's syndrome and idiopathic pulmonary hemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/971014" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Idiopathic pulmonary hemosiderosis: ultrastructural studies and responses to azathioprine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5030178" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Ultrastructure of the lung in idiopthic pulmonary hemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9892276" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Idiopathic pulmonary hemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6375320" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : C1q-binding immune complexes and other immunological studies in children with pulmonary hemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Idiopathic pulmonary haemosiderosis. Favourable effect of corticosteroids in two women aged 16 and 55 years
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1100325" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Idiopathic pulmonary hemosiderosis. Electron microscopic, immunofluorescent, and iron kinetic studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4588311" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Idiopathic pulmonary hemosiderosis: an electron microscopic and immunofluorescent study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35067768" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Prevalence of autoantibodies in pediatric patients with idiopathic pulmonary hemosiderosis: a scoping review of the literature in the period 1980-2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11039080" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Long-term outcome of idiopathic pulmonary hemosiderosis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31651292" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Diffuse alveolar haemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7267971" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Adult idiopathic pulmonary haemosiderosis and coeliac disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2036845" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Long-term clinical follow-up of adult idiopathic pulmonary hemosiderosis and celiac disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3706379" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Hemoptysis, pulmonary infiltrates, and diarrhea in a 36-year-old man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3606190" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pulmonary haemosiderosis and gluten.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8050533" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Bronchoalveolar lavage findings in a young adult with idiopathic pulmonary haemosiderosis and coeliac disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17199848" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Lane-Hamilton syndrome: simultaneous occurrence of coeliac disease and idiopathic pulmonary haemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18603390" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Screening for celiac disease in idiopathic pulmonary hemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5551274" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Idiopathic steatorrhoea and idiopathic pulmonary haemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20967850" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Benefit of gluten-free diet in idiopathic pulmonary hemosiderosis in association with celiac disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10070562" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Idiopathic pulmonary haemosiderosis. Epidemiology, pathogenic aspects and diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1173819" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Hyperreactivity to cow milk in young children with pulmonary hemosiderosis and cor pulmonale secondary to nasopharyngeal obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8977515" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Release of inflammatory mediators after cow's milk intake in a newborn with idiopathic pulmonary hemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7137164" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Human macrophage hemoglobin-iron metabolism in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5725735" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Retention of radioiron in the lungs of a woman with idiopathic pulmonary hemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2502204" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17542074" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Case 3-2007: a boy with respiratory insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20705801" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Lane-Hamilton syndrome: ferritin protects lung macrophages against iron and oxidation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12542808" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Idiopathic pulmonary haemosiderosis: an Oriental experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24125570" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : New insights into pediatric idiopathic pulmonary hemosiderosis: the French RespiRare(®) cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26692115" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Idiopathic pulmonary hemosiderosis in adults: review of cases reported in the latest 15 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26692115" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Idiopathic pulmonary hemosiderosis in adults: review of cases reported in the latest 15 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/375718" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Familial idiopathic pulmonary hemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/621956" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Idiopathic pulmonary hemosiderosis: two cases in a family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6842324" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Epidemiologic observations in idiopathic pulmonary hemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10346998" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Overview of investigations into pulmonary hemorrhage among infants in Cleveland, Ohio.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14767429" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Attributes of Stachybotrys chartarum and its association with human disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15017372" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Acute idiopathic pulmonary hemorrhage among infants. Recommendations from the Working Group for Investigation and Surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12205270" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Clinical profile of 30 infants with acute pulmonary hemorrhage in Cleveland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29678139" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Pulmonary hemosiderosis in children with Down syndrome: a national experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25294331" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : [Idiopathic pulmonary haemosiderosis in a one-year-old girl with Down syndrome].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26508184" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Idiopathic pulmonary hemosiderosis complicated by Down syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17536132" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Idiopathic pulmonary hemosiderosis: clinical profile and follow up of 26 children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17609633" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Silent idiopathic pulmonary hemosiderosis with iron-deficiency anemia but normal serum ferritin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Idiopathic pulmonary hemosiderosis and related syndromes
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7028070" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Pulmonary haemosiderosis and pulmonary haemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4750458" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Serum ferritin concentration and iron stores in normal subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6851680" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Serum ferritin in healthy Danes: relation to marrow haemosiderin iron stores.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25515792" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Idiopathic pulmonary haemosiderosis: spectrum of thoracic imaging findings in the adult patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19029052" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Honeycomb cysts in idiopathic pulmonary haemosiderosis: high-resolution CT appearances in two adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4690488" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Pulmonary function studies in idiopathic pulmonary hemosiderosis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/980094" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Detection of intrapulmonary hemorrhage with carbon monoxide uptake. Application in goodpasture's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12634470" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Pediatric idiopathic pulmonary hemosiderosis diagnosed by sputum analysis: plain radiography and computed tomography findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15249471" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Role of transbronchial biopsies in pediatric lung diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23961950" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Surveillance transbronchial biopsies in infant lung and heart-lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27521581" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Use of transbronchial cryobiopsy in the diagnosis of interstitial lung disease-a systematic review and cost analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31277659" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Bleeding risk of transbronchial cryobiopsy compared to transbronchial forceps biopsy in interstitial lung disease - a prospective, randomized, multicentre cross-over trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The alveolar epithelial lesion of idiopathic pulmonary hemosiderosis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8915239" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9116994" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Diffuse alveolar hemorrhage with underlying isolated, pauciimmune pulmonary capillaritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12023180" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Pitfalls in the diagnosis of idiopathic pulmonary haemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34491458" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Differentiation of idiopathic pulmonary hemosiderosis from rheumatologic and autoimmune diseases causing diffuse alveolar hemorrhage: establishing a diagnostic approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7831732" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : [Idiopathic pulmonary hemosiderosis. A cause of severe iron deficiency anemia in childhood].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10213256" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Long-term clinical course of patients with idiopathic pulmonary hemosiderosis (1979-1994): prolonged survival with low-dose corticosteroid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7957431" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Liposteroid against refractory pulmonary haemorrhage in idiopathic pulmonary haemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33184706" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Idiopathic pulmonary hemosiderosis: a review of the treatments used during the past 30 years and future directions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10492278" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Prognosis in pediatric idiopathic pulmonary hemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16850442" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Extracorporeal membrane oxygenation to rescue profound pulmonary hemorrhage due to idiopathic pulmonary hemosiderosis in a child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9313410" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The challenges of idiopathic pulmonary hemosiderosis and lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27644948" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Idiopathic pulmonary haemosiderosis in paediatric patients: how to make an early diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16970298" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Life threatening exacerbation in idiopathic pulmonary hemosiderosis salvaged by cyclophosphamide infusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26289251" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A physician survey reveals differences in management of idiopathic pulmonary hemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23942745" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Extracorporeal life support for a 5-week-old infant with idiopathic pulmonary hemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14743057" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Legionella pneumonia: infection during immunosuppressive therapy for idiopathic pulmonary hemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14528889" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Management of idiopathic pulmonary haemosiderosis in pregnancy: report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1437333" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Long-term prednisone and azathioprine treatment of a patient with idiopathic pulmonary hemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4800237" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Immunosuppressive treatment of idiopathic pulmonary hemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11665500" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Idiopathic pulmonary hemosiderosis in an adult. Favourable response to azathioprine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14565801" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Treatment of pediatric idiopathic pulmonary hemosiderosis with low-dose cyclophosphamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18972408" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Maintenance therapy with dose-adjusted 6-mercaptopurine in idiopathic pulmonary hemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22573417" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Successful treatment of idiopathic pulmonary capillaritis with intravenous cyclophosphamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12490803" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Recurrence of idiopathic pulmonary hemosiderosis in a young adult patient after bilateral single-lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34924103" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Short Review of Liposteroid: A Novel Targeted Glucocorticoid Preparation for Treatment of Autoimmune and Inflammatory Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23812505" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Long-term liposteroid therapy for idiopathic pulmonary hemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2859435" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Budesonide inhalation to treat idiopathic pulmonary haemosiderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7660222" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Treatment of idiopathic pulmonary hemosiderosis with inhaled flunisolide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18847157" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Sequential pulmonary function measurements in an infant treated with idiopathic pulmonary hemosiderosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
